Related Experiment Video
Updated: Mar 2, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
Published on: September 20, 2019
[THE INFLUENCE OF THE ISRAELI LEGISLATION ON THE RELATIONSHIP BETWEEN PHYSICIANS AND PHARMACEUTICAL COMPANIES]
Rachel Nissanholtz-Gannot1,2, Ariel Yankellevich2, Nurit Nirel2
1Ariel University.
Introduction:
The relationship between physicians and pharmaceutical-companies raises many dilemmas. There are two types of solutions to these dilemmas: self-regulation and government regulation. Our goal was to review in what way legislative intervention and self-regulation standardize and affect the relationship. In addition, we examined the positions of relevant stakeholders regarding: 1. The relationship between physicians and pharmaceutical companies; 2. Future measures we should take to address the ethical dilemmas inherent in this relationship.
Methods:
1. In-depth interviews with 42 senior representatives of all the relevant stakeholders, with emphasis on their organizational identity, since their points of view are influenced and shaped by organizational and professional positioning. We analyzed the interviews using the Narralizer program. 2. Analysis of three databases: The Ministry of Health, The Israel Medical Association and Pharma-Israel, regarding donations made to various parties in the health system.
Results:
The influence of Israeli legislation on the relationship between physicians and pharmaceutical companies is almost imperceptible. However, in recent years, there have been changes in this relationship stemming from international self-regulation, which leads to: contractual relationships, decreases in hospitality and tighter internal control over this relationship.
Conclusions:
Regulation in Israel is not achieving its goal satisfactorily. Solutions to reduce the influence of this relationship exist. However, the first step is for the regulator to decide to what extent, if any, he wants to deal with this issue. If the regulator chooses to take the lead on this issue, we will soon face additional legislation that might limit the amount of money that the pharmaceutical companies can donate to healthcare organizations.
More Related Videos
Related Concept Videos
Drug Regulation
Drug Control Governance: Regulatory Bodies and Their Impact
Drug Products: Biologics, Biosimilars and Interchangeables
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Prescription, Nonprescription and Orphan Drugs
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

